Boston Scientific Corporation BSX
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, Boston Scientific Corporation gets an algorithmic score of 54/100. It trades at 43.88 $, with a bearish technical trend (RSI 41.7) and 38.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Sustained revenue growth (16.5% compound annual).
- Attractive free-cash-flow yield (5.4%).
- Low beta (0.57): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 17.77 |
| Forward P/E | 12.86 |
| PEG | 0.63 |
| P/B | 2.55 |
| EV/EBITDA | 13.29 |
| P/S | 3.03 |
| ROE % | 15.34 |
| ROA % | 6.19 |
| Gross margin % | 69.19 |
| Operating margin % | 22.90 |
| Net margin % | 17.50 |
| Revenue growth % (y/y) | 7.50 |
| Earnings growth % (y/y) | 15.10 |
| Revenue CAGR % | 16.54 |
| Earnings CAGR % | 60.72 |
| Debt/Equity % | 50.15 |
| Current ratio | 1.24 |
| FCF yield % | 5.35 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -6.3 % |
| 3 months | +2.8 % |
| 6 months | -30.3 % |
| YTD | -53.7 % |
| 1 year | -55.3 % |
| 3 years | -18.1 % |
| 5 years | +1.2 % |
Risk
| 1-year volatility | 38.3 % |
| Beta | 0.57 |
| 5-year max drawdown | -60.6 % |
| Sharpe 1A | -2.00 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.